Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.
Melanoma Res
; 22(5): 410-1, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-22828249
ABSTRACT
The BRAF inhibitor vemurafenib can cause severe cutaneous reactions, including Stevens-Johnson syndrome, particularly when administered after ipilimumab, which usually prevents further drug administration. We report the case of a patient with Stevens-Johnson syndrome due to vemurafenib, who was retreated with vemurafenib with a program of slow desensitization with dexamethasone and diphenhydramine. Vemurafenib was tolerated at a 50% dose after a 3-week desensitization. Desensitization may be possible in patients who develop Stevens-Johnson syndrome after vemurafenib treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sulfonamidas
/
Dexametasona
/
Dessensibilização Imunológica
/
Síndrome de Stevens-Johnson
/
Difenidramina
/
Indóis
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article